Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug: report

 Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug: report

By Jan Wolfe

(Reuters) - A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Rapatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Sanofi and Regeneron had stipulated that if the Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.

Thousand Oaks, California-based Amgen won a similar verdict in 2016, as well as a court order blocking Praluent sales, but an appeals court set aside the victory and ordered a new trial.

(Reporting by Jan Wolfe; Editing by Cynthia Osterman and Richard Chang)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date: Feb 26, 2019 04:06:01 IST